Diabetes mellitus is associated with increased bleeding in pulmonary embolism receiving conventional anticoagulant therapy: findings from a "real-world" study.

Abstract:

:Bleeding refers to the most important complication during anticoagulation therapy in patients with pulmonary embolism (PE). However, the incidence and risk factors of bleeding in Chinese population with anticoagulant therapy remains unknown. Although diabetes mellitus (DM) has been demonstrated to increase the risk of PE, little information of its influence on anticoagulation-associated bleeding risk can be available. In our study, 563 acute PE patients, who fulfilled the including criteria were enrolled from a single center and received conventional anticoagulant therapy. And there were 539 patients completed the 3 months following-up. The cumulative incidences of major bleeding (MB) and clinically relevant non-major bleeding (CRNMB) were 3.0% (95% CI 1.01-3.05) and 14.0% (95% CI 1.47-5.21), respectively. Besides, anemia (OR 3.52, 95% CI 1.12-11.41) and recent history of MB (OR 8.14, 95% CI 1.41-31.95) were independently associated with MB. Age >65 year (OR 1.51, 95% CI 1.12-3.11), cancer (OR 2.01, 95% CI 1.12-4.01) and therapeutic range (TTR) during 3 months (OR 0.93, 95% CI 0.91-0.98) were independently associated with CRNMB. Additionally, DM was an independent risk factor for both MB (OR 2.11, 95% CI 1.10-4.12) and CRNMB (OR 2.11, 95% CI 1.10-4.12). Notably, the incidence of MB or CRNMB was significantly higher in DM patients than non-DM patients. At the end of 3-month follow-up, the HbA1C in CRNMB group was 8.3%, yet it was 7.0% in non-CRNMB group among diabetic patients (p = 0.04). In conclusions, the bleeding rates are high in patients with acute PE who receive anticoagulant therapy. In addition to the already known bleeding risk factors, DM can also increase the bleeding risk significantly. Thus, good glycemic control may be essential after prescription of anticoagulant therapy.

journal_name

J Thromb Thrombolysis

authors

Zhang Z,Zhai Z,Yang Y,Wan J,Xie W,Zhu J,Shen YH,Wang C

doi

10.1007/s11239-017-1473-5

subject

Has Abstract

pub_date

2017-05-01 00:00:00

pages

540-549

issue

4

eissn

0929-5305

issn

1573-742X

pii

10.1007/s11239-017-1473-5

journal_volume

43

pub_type

杂志文章
  • Mild hypothermia markedly reduces ischemia related coronary t-PA release.

    abstract::In experimentally induced myocardial ischemia, mild hypothermia (33-35 degrees C) has a robust cardioprotective effect. Tissue plasminogen activator (t-PA) is a profibrinolytic enzyme that is released from the vascular endothelial cells in response to ischemia and other injurious stimuli. t-PA has also been found to h...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-009-0350-2

    authors: van der Pals J,Götberg M,Olivecrona GK,Brogren H,Jern S,Erlinge D

    更新日期:2010-04-01 00:00:00

  • Clinical validation of immunoassay HemosIL® AcuStar HIT-IgG (PF4-H) in the diagnosis of Heparin-induced thrombocytopenia.

    abstract::Heparin induced thrombocytopenia (HIT) is a life and limb-threatening complication of heparin exposure. The misdiagnosis of this disease can have major consequences on the patients. The objective of this study was to evaluate a diagnostic strategy that combines the 4Ts score with the result of HemosIL® AcuStar HIT-IgG...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-020-02349-4

    authors: Marashi-Sabouni Z,Vayne C,Ibrahim-Kosta M,Guidon C,Loundou A,Guery EA,Morange PE,Camoin-Jau L

    更新日期:2021-01-01 00:00:00

  • Survey of confidence in use of stroke and bleeding risk calculators, knowledge of anticoagulants, and comfort with prescription of anticoagulation in challenging scenarios: SUPPORT-AF II study.

    abstract::Half of patients with atrial fibrillation (AF) and elevated stroke risk do not receive anticoagulation (AC). Explanations for undertreatment may relate to provider lack of confidence with or knowledge of the CHA2DS2-VASc stroke calculator, unfamiliarity with direct oral anticoagulants (DOACs), or uncertainty about use...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-019-01950-6

    authors: Amroze A,Mazor K,Crawford S,O'Day K,McManus DD,Kapoor A

    更新日期:2019-11-01 00:00:00

  • Embolic events caused by aortic thrombi: an underestimated entity?

    abstract::Stroke and other thromboembolic events are mainly caused by emboli from heart, aorta and other arteries. In this paper we describe a group of 5 middle-aged patients suffering from emboli caused by large thrombi in the aorta. Since the development of giant thrombi under high flow conditions in the aorta is a pathophysi...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-012-0775-x

    authors: Stoevesandt D,Klempt C,Scheubel R,Herr W,Hettwer S,Werdan K,Silber RE,Kraya T,Thews O,Schlitt A

    更新日期:2013-02-01 00:00:00

  • Clinical application of procedural platelet monitoring during percutaneous coronary intervention among patients at increased bleeding risk.

    abstract::The goal of platelet function testing in the catheterization laboratory is to provide information about the platelet contributions to the risk of thrombotic or hemorrhagic events and optimization of anti-platelet therapy for percutaneous interventions. We present several illustrative cases in which platelet monitoring...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1023/a:1011228817265

    authors: Mukherjee D,Chew DP,Robbins M,Yadav JS,Raymond RE,Moliterno DJ

    更新日期:2001-04-01 00:00:00

  • Multiple and recurrent systemic thrombotic events associated with congenital anomaly of inferior vena cava.

    abstract::We describe a case of a 67-year-old woman with a history of cerebral infarction and pulmonary embolism that presented with chest pain. Subsequent evaluation resulted in a diagnosis of acute myocardial infarction and occult DVT, and imaging revealed a rare congenital absence of the infra-renal portion of the inferior v...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-005-1380-z

    authors: Takehara N,Hasebe N,Enomoto S,Takeuchi T,Takahashi F,Ota T,Kawamura Y,Kikuchi K

    更新日期:2005-04-01 00:00:00

  • Why develop antidotes and reversal agents for non-vitamin K oral anticoagulants?

    abstract::Over the past several years, non-vitamin K oral anticoagulants (NOACs) have been introduced into clinical practice for the treatment of venous thromboembolism and prevention of stroke in patients with nonvalvular atrial fibrillation. Clinical trials have shown these agents to have similar or less risk of major bleedin...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,评审

    doi:10.1007/s11239-015-1296-1

    authors: Washam JB,Piccini JP

    更新日期:2016-02-01 00:00:00

  • Regulatory, legislative, and policy updates with anticoagulant use.

    abstract::Thromboembolism afflicts millions of patients annually in the United States and is associated with a significant cost burden. Recent advances in oral anticoagulation have provided clinicians with more options for management of these diseases. Accordingly, regulatory, legislative, and policy-making organizations have i...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,评审

    doi:10.1007/s11239-015-1198-2

    authors: Fanikos J,Buckley LF,Aldemerdash A,Terry KJ,Piazza G,Connors JM,Goldhaber SZ

    更新日期:2015-04-01 00:00:00

  • Impact of primary PCI volume on hospital mortality in STEMI patients: does time-to-presentation matter?

    abstract::The exact relationship between primary percutaneous coronary intervention (PCI) volume and mortality remains unclear. No data are available on how this relationship could be affected by time-to-presentation. The primary aim of this study was to evaluate the impact of hospital primary PCI volume on in-hospital mortalit...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1007/s11239-011-0598-1

    authors: Navarese EP,De Servi S,Politi A,Martinoni A,Musumeci G,Boschetti E,Belli G,D'Urbano M,Piccaluga E,Lettieri C,Klugmann S

    更新日期:2011-08-01 00:00:00

  • Aspirin administered to women at 100 mg every other day produces less platelet inhibition than aspirin administered at 81 mg per day: implications for interpreting the women's health study.

    abstract:OBJECTIVE:We aimed to determine the relative level of platelet inhibition achieved with low-dose aspirin (81 mg daily) compared with a very low-dose (100 mg every other day). BACKGROUND:The Womens Health Study (WHS) found that a dose of 100 mg every other day of aspirin provided protection against stroke as primary pr...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 临床试验,杂志文章

    doi:10.1007/s11239-008-0262-6

    authors: Swaim L,Hillman RS

    更新日期:2009-07-01 00:00:00

  • Influence of chronic kidney disease on anticoagulation levels and bleeding after primary percutaneous coronary intervention in patients treated with unfractionated heparin.

    abstract::Unfractionated heparin (UFH) plasma protein binding and elimination might be impaired in patients with chronic kidney disease (CKD-defined as creatinine clearance <60 ml/min). It is currently unknown at which UFH bolus dose persistent prolongation of activated partial thromboplastin time (aPTT) occurs in ST-segment el...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 临床试验,杂志文章

    doi:10.1007/s11239-015-1255-x

    authors: Kikkert WJ,van Brussel PM,Damman P,Claessen BE,van Straalen JP,Vis MM,Baan J Jr,Koch KT,Peters RJ,de Winter RJ,Piek JJ,Tijssen JG,Henriques JP

    更新日期:2016-04-01 00:00:00

  • Impact of renal function on argatroban therapy during percutaneous coronary intervention.

    abstract::Argatroban, a hepatically metabolized direct thrombin inhibitor, is approved for anticoagulation in patients with or at risk of heparin-induced thrombocytopenia (HIT) undergoing percutaneous coronary intervention (PCI). We investigated the effect of renal function on argatroban therapy during PCI. From previous argatr...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-009-0357-8

    authors: Hursting MJ,Jang IK

    更新日期:2010-01-01 00:00:00

  • The thrombolytic effect of aspirin in animal model.

    abstract:BACKGROUND:The aspirin induced platelet aggregation has been reported to be mediated through the inhibition of platelet prostaglandin synthesis. This compound has also been recently reported to stimulate nitric oxide synthesis in platelets. Since nitric oxide has been reported to produce fibrinogen/fibrinolytic effect,...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-007-0023-y

    authors: Karmohapatra SK,Kahn NN,Sinha AK

    更新日期:2007-10-01 00:00:00

  • EPC mobilization after erythropoietin treatment in acute ST-elevation myocardial infarction: the REVEAL EPC substudy.

    abstract::Erythropoietin (EPO) was hypothesized to mitigate reperfusion injury, in part via mobilization of endothelial progenitor cells (EPCs). The REVEAL trial found no reduction in infarct size with a single dose of EPO (60,000 U) in patients with ST-segment elevation myocardial infarction. In a substudy, we aimed to determi...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1007/s11239-013-0944-6

    authors: Povsic TJ,Najjar SS,Prather K,Zhou J,Adams SD,Zavodni KL,Kelly F,Melton LG,Hasselblad V,Heitner JF,Raman SV,Barsness GW,Patel MR,Kim RJ,Lakatta EG,Harrington RA,Rao SV

    更新日期:2013-11-01 00:00:00

  • Patients with perceived high-bleeding risk and computerized decision support for stroke prevention in atrial fibrillation: an AF-ALERT substudy : Piazza: outcomes of high-bleeding risk AF patients.

    abstract::A perceived increased risk of bleeding is one of the most frequent reasons for withholding anticoagulation for stroke prevention in atrial fibrillation (AF). We previously conducted a randomized controlled trial of alert-based computerized decision support to increase prescription of anticoagulation in hospitalized pa...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-020-02296-0

    authors: Piazza G,Hurwitz S,Carroll B,Goldhaber SZ

    更新日期:2020-09-30 00:00:00

  • A real world data of dabigatran etexilate: multicenter registry of oral anticoagulants in nonvalvular atrial fibrillation.

    abstract::Atrial fibrillation (AF) is a common cardiac arrhythmia. Dabigatran etixalate (DE) is one of the new oral anticoagulant drugs being used in nonvalvular AF (NVAF). There is no adequate real world data in different populations about DE. The aim of this registry was to evaluate the efficacy and safety of DE Consecutive N...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s11239-016-1361-4

    authors: Yavuz B,Ayturk M,Ozkan S,Ozturk M,Topaloglu C,Aksoy H,Şabanoglu C,Tanalp AC,Dal K,Ata N,Yavuz BB

    更新日期:2016-10-01 00:00:00

  • Standard or extended-duration prophylaxis in medical patients? A review of the evidence.

    abstract::Acutely ill medical patients are at significant risk of venous thromboembolism (VTE). Thromboprophylaxis can substantially reduce the incidence of VTE, but to be optimally effective must consist of the correct choice of agent, at an appropriate dose, and for sufficient duration. Increasing evidence suggests that VTE r...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,评审

    doi:10.1007/s11239-011-0594-5

    authors: Stark JE,Smith WJ

    更新日期:2011-10-01 00:00:00

  • Differing coagulation profiles of patients with monoclonal gammopathy of undetermined significance and multiple myeloma.

    abstract::The link between myeloma and thrombosis is well established. Monoclonal gammopathy of undetermined significance (MGUS) has also been associated with an increased risk of thrombosis. It was recently demonstrated that patients with myeloma display changes in thromboelastometry that may indicate a prothrombotic state. Th...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-014-1140-z

    authors: Crowley MP,Quinn S,Coleman E,Eustace JA,Gilligan OM,O'Shea SI

    更新日期:2015-02-01 00:00:00

  • Efficacy and safety of rivaroxaban on the resolution of left atrial/left atrial appendage thrombus in nonvalvular atrial fibrillation patients.

    abstract::Data on LA/LAA thrombus resolution after rivaroxaban treatment has not been established. The aim of the present study was to compare the efficacy and safety on the resolution of LA/LAA thrombus between rivaroxaban and warfarin in nonvalvular atrial fibrillation (AF) patients. 80 AF patients with LA/LAA thrombus betwee...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s11239-019-01876-z

    authors: Ke HH,He Y,Lv XW,Zhang EH,Wei Z,Li JY

    更新日期:2019-08-01 00:00:00

  • Low incidence of thromboembolism in multiple myeloma patients receiving immunomodulatory drugs; a retrospective single-institution analysis.

    abstract::Anti-platelet agents or anticoagulants are administered for patients with multiple myeloma (MM) receiving immunomodulatory drugs (IMiDs) to prevent thrombotic events (TEs). However, there is a discrepancy between current guidelines and clinical practice in thromboprophylaxis and the varied incidence of TEs depending o...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-019-01809-w

    authors: Takaishi K,Tsukamoto S,Ohwada C,Takeuchi M,Kawasaki Y,Nagai Y,Mishina T,Yamazaki M,Isshiki Y,Kayamori K,Kimura K,Hino Y,Oshima-Hasegawa N,Mitsukawa S,Takeda Y,Mimura N,Iseki T,Nakaseko C,Sakaida E

    更新日期:2019-07-01 00:00:00

  • The lack of endothelization after drug-eluting stent implantation as a cause of fatal late stent thrombosis.

    abstract::The authors present a fatal case of late thrombosis of paclitaxel-eluting stent implanted in the left main stem occurring 6 months after the procedure and 3 weeks after the cessation of clopidogrel. An autopsy has shown the lack of endothelization of deployed stent. ...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-007-0080-2

    authors: Jakabcin J,Bystron M,Spacek R,Veselka J,Kvasnak M,Kala P,Malý J,Cervinka P

    更新日期:2008-10-01 00:00:00

  • Inflammatory cytokines, endothelial markers and adhesion molecules in rheumatoid arthritis: effect of intensive anti-inflammatory treatment.

    abstract::Tumour necrosis factor alpha (TNF-alpha) and interlekin-6 (IL-6) are key inflammatory cytokines in the pathogenesis of rheumatoid arthritis (RA), a disease also associated with endothelial perturbation and increased serum levels of adhesion molecules. As relationships between these processes and molecules are unclear,...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1007/s11239-009-0370-y

    authors: Foster W,Carruthers D,Lip GY,Blann AD

    更新日期:2010-05-01 00:00:00

  • Rivaroxaban in the Treatment of Heparin-Induced Thrombocytopenia.

    abstract::Heparin-induced thrombocytopenia (HIT) is a prothrombotic condition and it is associated with increased in vivo thrombin generation that needs to be treated with non-heparin anticoagulants such as direct thrombin inhibitors (DTIs). DTIs require parenteral administration and are associated with a non negligible risk of...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-015-1208-4

    authors: Sartori M,Favaretto E,Cini M,Legnani C,Cosmi B

    更新日期:2015-10-01 00:00:00

  • The ADP receptor P2Y(1) mediates t-PA release in pigs during cardiac ischemia.

    abstract:BACKGROUND:The endothelial ADP receptor P2Y(1) is responsible for a large part of the reactive hyperemia following cardiac ischemia. Tissue plasminogen activator (t-PA) increases during reactive hyperemia. We postulated that the release of t-PA during reactive hyperemia could be mitigated through blocking the coronary ...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-007-0010-3

    authors: Olivecrona GK,Götberg M,Harnek J,Jacobson KA,Jern S,Erlinge D

    更新日期:2007-10-01 00:00:00

  • A Randomized, Blinded Study of Two Doses of Novastan(R) (Brand of Argatroban) Versus Heparin as Adjunctive Therapy to Recombinant Tissue Plasminogen Activator (Accelerated Administration) in Acute Myocardial Infarction: Rationale and Design of the Myocard

    abstract::Thrombolytic therapy has become a standard treatment for selected patients with acute myocardial infarction (MI). Various thrombolytic agents have been shown to decrease mortality. However, current thrombolytic agents still suffer significant shortcomings, such as a low optimal reperfusion rate delayed reperfusion. an...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1023/a:1008872031770

    authors: Serebruany VL,Jang IK,Giugliano RP,Massey TJ,Schwarz Jr RP

    更新日期:1998-01-01 00:00:00

  • Effect of Poloxamer 188 on Collateral Blood Flow, Myocardial Infarct Size, and Left Ventricular Function in a Canine Model of Prolonged (3-Hour) Coronary Occlusion and Reperfusion.

    abstract::Poloxamer 188 is a surfactant with hemorheological, antithrombotic, and neutrophil-inhibitory properties. This agent has been demonstrated to reduce infarct size and to improve left ventricular function in animal models of myocardial infarction and reperfusion, and recently in a randomized trial of patients receiving ...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1023/A:1008848026759

    authors: Kelly RF,Hursey TL,Patel RB,Parrillo JE,Schaer GL

    更新日期:1998-07-01 00:00:00

  • Lipid rich plaque, female gender and proximal coronary stent edge dissections.

    abstract::We hypothesized that women are more prone to develop coronary dissections during PCI due to potential balloon-oversizing or gender specific plaque and vascular characteristics. To date, a gender related difference in edge dissection has not been systematically studied. The Massachusetts General Hospital Optical Cohere...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1007/s11239-013-0882-3

    authors: Zeglin-Sawczuk M,Jang IK,Kato K,Yonetsu T,Kim S,Choi SY,Kratlian C,Lee H,Dauerman HL

    更新日期:2013-11-01 00:00:00

  • Soluble E-selectin is not a marker of unstable coronary plaque in serum of patients with ischemic heart disease.

    abstract::Increased level of soluble cell adhesion molecules may be a marker for atherosclerosis and/or reflect complication of the atherosclerotic plaque. To test whether expression of cell adhesion molecules is more pronounced in unstable versus stable coronary plaques, we measured the serum level of soluble E-selectin (sE-se...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1023/a:1018656530541

    authors: Galvani M,Ferrini D,Ottani F,Nanni C,Ramberti A,Amboni P,Iamele L,Vernocchi A,Nicolini FA

    更新日期:2000-01-01 00:00:00

  • Laboratory measurement of apixaban using anti-factor Xa assays in acute ischemic stroke patients with non-valvular atrial fibrillation.

    abstract::Apixaban is effective and safe for preventing stroke, and its usage has increased exponentially in recent years. However, data concerning the therapeutic range of apixaban is limited. This study determined the trough and peak levels of apixaban-specific anti-factor Xa activity (AFXaA) in acute ischemic stroke patients...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-017-1590-1

    authors: Shin H,Cho MC,Kim RB,Kim CH,Choi NC,Kim SK,Koh EH

    更新日期:2018-02-01 00:00:00

  • Anticoagulant therapy management of venous thromboembolism recurrence occurring during anticoagulant therapy: a descriptive study.

    abstract::Limited evidence exists regarding management of recurrent venous thromboembolism (VTE) that occurs during anticoagulant therapy. We aimed to describe patient characteristics, drug therapy management, and outcomes of patients with VTE recurrence during anticoagulant therapy. We identified 30 relevant episodes of VTE re...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-021-02377-8

    authors: Lai N,Jones AE,Johnson SA,Witt DM

    更新日期:2021-01-23 00:00:00